skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

About Ian

Japan

34+ years of experience

Ian oversees content for the Asia-Pacific area, including in the commercial and policy/regulation areas, with a particular interest in company and pricing topics. He has been covering the region for more than 20 years as a writer and editor in the pharma sector.
Ian first moved to Japan in the 1990s and has covered a broad range of pharma industry topics, both across this market and the rest of Asia, including corporate, R&D, pricing and policy developments. After a stint as a Tokyo-based Japan and Asia editor for Scrip, he became managing editor of PharmAsia News (now part of Scrip/Pink Sheet) in 2014, and is a recipient of multiple Informa internal awards. He has a long personal and professional background in Asia, having grown up in Hong Kong, and follows regional regulatory harmonization and trade initiatives with interest. Ian lives in Tokyo with his wife and two sons.

Analyst Articles

Articles by Ian

  • ターゲット市場の実像をつかむ

    Japan Pharma Outlook Webinar Recording

    By Ian Haydock 15 Jun 2022

    Listen to this insightful presentation of the unique challenges and opportunities faced by Japan Pharma, hosted by the expert analysts from Pharma Intelligence.

    Topic Drug Development Landscape

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip's Five Must-Know Things

    By Ian Haydock 17 Jan 2022

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip's Five Must-Know Things

    By Ian Haydock 10 Jan 2022

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong

    By Ian Haydock 01 Dec 2021

    SC2112_asia_HTBK2R_1200

    Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months. 

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip's Five Must-Know Things

    By Ian Haydock 28 Nov 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 15 Nov 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: Pfizer’s "game-changing" COVID-19 oral antiviral results; Novartis sells Roche stake; Novartis trumps productive pipeline; Bayer sees blockbuster status for hot flashes drug; and continued hesitance over Aduhelm in the US.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 01 Nov 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: Lilly goes head-to-head in Alzheimer’s; Roche eyes new opportunities for Lucentis; Novartis doubles down on innovation; BMS seeks growth amid generic threats; and the new head of Boehringer Ingelheim India talks to Scrip.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 26 Oct 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: a slow start for Biogen’s Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB faces bimekizumab delays; and progress and setbacks in gene therapy.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 17 Oct 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: US tax policies challenge pharma; J&J’s long-time R&D head to retire; Legend Biotech’s CEO talks about plans; BMS disappointment in ulcerative colitis; and another gene therapy partnership for Takeda.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 04 Oct 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: the prospects for Merck’s Acceleron acquisition; the pandemic and biotech capital in-flow; an interview with Menarini’s CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis Pharma’s president.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 26 Sep 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: an interview with the president of Novartis Pharma; Biogen highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron nip at Keytruda’s heels in first-line lung cancer; and a look at the market prospects for wet AMD.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 06 Sep 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: new US warnings for JAK inhibitors; strong new heart failure results for Jardiance; good head-to-head results for Pfizer in atopic dermatitis; US payers and drug exclusion lists; and a look ahead at key expected hematology launches.  

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 16 Aug 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: a history of Alzheimer’s drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche’s Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 09 Aug 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 25 Jul 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.